Please use this identifier to cite or link to this item:
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
- IOC - Artigos de Periódicos [12982]
Metadata
Show full item record
PHENOTYPIC AND GENOTYPIC DRUG SUSCEPTIBILITY ASSESSMENT OF MYCOBACTERIUM BOVIS BACILLUS CALMETTE-GUÉRIN CLINICAL STRAINS
Author
Affilliation
Abstract
Purpose: Mycobacterium bovis Bacillus Calmette-Guérin (BCG) is the only vaccine
licensed against tuberculosis. Despite the protection offered by the vaccine, in some circumstances
children and immunocompromised individuals can develop associated infections,
known as BCGitis. Drug susceptibility patterns of BCG clinical strains have rarely been
described. We aimed to describe the susceptibility pattern of BCG clinical strains isolated in
two different countries.
Methods: We performed culture-based drug susceptibility testing of thirty one BCG strains
isolated from patients in Brazil (n=5, 16%) and Argentina (n=26, 84%) using the broth
micro-dilution method (phenotypic method). Final antibiotic concentrations for susceptibility
testing ranged from 0.5 to 16 mg/L for amikacin, 0.3125 to 10 mg/L for ethambutol, 0.05 to
1.6 mg/L for isoniazid and 0.25 to 8 mg/L for rifampicin, streptomycin and ofloxacin.
Additionally, we compared the results with genetic data obtained by whole genome
sequencing.
Results: By using the phenotypic method we detected one strain resistant to ethambutol,
three strains resistant to rifampicin and one resistant to isoniazid. Additionally, two strains
that were phenotypically resistant to both isoniazid and rifampicin carried mutations in the
katG and rpoB genes simultaneously.
Conclusion: There is evidence of the emergence of BCG-resistant strains isolated from
vaccine-related complications. We recommend drug susceptibility testing of the BCG strain
causing the infection in order to prevent treatment failure.
Share